Should you consider ADMA BIOLOGICS INC (NASDAQ:ADMA) for growth investing?

In this article we will dive into ADMA BIOLOGICS INC (NASDAQ:ADMA) as a possible candidate for growth investing. Investors should always do their own research, but we noticed ADMA BIOLOGICS INC showing up in our Louis Navellier growth screen, which makes it worth to investigate a bit more.

Key Considerations for Growth Investors.

• With a solid Return on Equity (ROE) of 56.64%, ADMA exemplifies its ability to generate favorable returns on shareholder investments. This metric demonstrates the company's commitment to maximizing shareholder value.
• With a track record of beating EPS estimates 3 times in the last 4 quarters, ADMA showcases its consistent ability to deliver earnings surprises. This reflects the company's strong execution and its competitive position in the market.
• ADMA has demonstrated strong 1-year revenue growth of 65.16%, reflecting revenue momentum and its ability to generate consistent top-line expansion. This growth underscores the company's strong market position and its potential for future success.
• The recent q2q revenue growth of 59.06% of ADMA showcases the company's ability to generate increasing revenue in a short period, reflecting its positive growth trajectory.
• With positive growth in its operating margin over the past year, ADMA showcases its ability to improve profitability through effective cost control and operational efficiency. This growth underscores the company's commitment to enhancing its financial performance.
• The free cash flow (FCF) of ADMA has seen steady growth over the past year, indicating enhanced cash flow generation and financial health. This trend underscores the company's effective capital management and its ability to generate sustainable cash flows.
• The recent financial report of ADMA demonstrates a 275.0% increase in quarterly earnings compared to the previous quarter. This growth indicates positive momentum in the company's financials and suggests a promising upward trend
• Over the past 3 months, analysts have adjusted their EPS Estimate for ADMA with a 9.31% change. This highlights the evolving outlook on the company's EPS potential.
• ADMA has achieved %EPSYGROWTHTTM% growth in EPS over the past 12 months, reflecting a sustained improvement in earnings performance.
• The earnings per share (EPS) growth of ADMA is accelerating: the current Q2Q growth of 275.0% is above the previous year Q2Q growth of -33.33%. Earnings momentum and acceleration are key for high growth systems.

A complete fundamental analysis of ADMA

ChartMill assigns a Fundamental Rating to every stock. This score, ranging from 0 to 10, is updated daily and is determined by evaluating multiple fundamental indicators and properties.

Taking everything into account, ADMA scores 6 out of 10 in our fundamental rating. ADMA was compared to 563 industry peers in the Biotechnology industry. While ADMA has a great health rating, its profitability is only average at the moment. ADMA is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings could make ADMA a good candidate for growth investing.

Our latest full fundamental report of ADMA contains the most current fundamental analsysis.

Our Lois Navellier screen will find you more ideas suited for growth investing.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.